Download Files:
KA2507
$26 – $2,000
Products Details
Product Description
– KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models[1].
Web ID
– HY-138799
Storage Temperature
– 4°C (Powder, protect from light)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C16H14N6O2
References
– [1]Apostolia M Tsimberidou, et al. Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. Clin Cancer Res. 2021 May 4.
CAS Number
– 1636894-46-6
Molecular Weight
– 322.32
Compound Purity
– 98.09
SMILES
– O=C(NO)C1=CC=C(CN(C2=NC=CN=C2)C3=NC=CN=C3)C=C1
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 66.67 mg/mL (ultrasonic)
Target
– HDAC
Isoform
– HDAC6;HDAC8
Pathway
– Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
